Century Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances Amid Cost Cuts

summarizeSummary

Century Therapeutics' Q2 2026 filing shows a cash runway into 2029, a swing to a net loss after a one-time gain last year, and continued cost-cutting. The balance sheet reflects massive dilution from a January private placement, but the company has enough capital to advance its lead diabetes program.

check_boxKey Events · Earnings and Guidance · IPSC

• Cash Runway Extended to Q1 2029

  Cash, equivalents and investments totaled $197.2 million at June 30, 2026, which management expects to fund operations into the first quarter of 2029, removing near-term financing risk.

• Net Loss Swings on Prior-Year Gain

  H1 2026 net loss was $56.2 million vs. a $44.0 million profit in H1 2025, which included a one-time $109.2 million revenue recognition from the terminated BMS collaboration.

• R&D Spending Cut 31%

  Research and development expenses fell to $36.7 million from $53.4 million, driven by staff reductions and portfolio prioritization toward lead candidate CNTY-813.

• Restructuring Charges Hit Earnings

  A $11.1 million loss on partial lease termination and a $3.8 million gain from derecognizing a contingent liability (failed milestone) reflect ongoing operational streamlining.

auto_awesomeAnalysis · IPSC · Life Sciences

A net loss of $56.2 million for the first half of 2026 marks a sharp reversal from the $44.0 million profit a year ago, which was inflated by a one-time $109.2 million BMS termination payment. The critical survival metric for this pre-revenue biotech is the $197.2 million in cash and investments at June 30, which management says funds operations into the first quarter of 2029. R&D spending dropped 31% as the company prioritized its lead diabetes candidate CNTY-813 and reduced headcount. Further highlighting the restructuring, a $11.1 million loss from downsizing its Philadelphia headquarters and the derecognition of a $3.8 million contingent liability—a milestone that was not achieved—hit the books. The balance sheet reflects the $126.4 million January private placement that more than doubled the share count to 181 million, creating significant dilution but providing the runway. In a continuing pattern of executive changes, the CSO moved to a part-time role. The stock trades at $1.98, well below the $2.60 warrant exercise price from the January raise, limiting near-term warrant exercise proceeds.